CA125在卵巢癌诊断中的应用困境与突破

doi:10.7504/fk2016040110

摘要/Abstract

摘要：

CA125是应用最广泛的卵巢癌血清标志物。但近年来发现其诊断特异度较低，不少良性疾病患者及妊娠期或月经期妇女血清CA125也明显升高。这一状况给卵巢癌术前诊断及人群筛查带来诸多困扰。鉴于CA125分子是一种高度糖基化的黏蛋白，其糖基化修饰在卵巢癌中具有明显的特征结构，近期研究证实被特征性糖链所修饰的CA125亚型将有助于提高卵巢癌诊断准确度，有望突破上述困境。

关键词: 卵巢癌, 癌抗原125, 糖基化修饰, Tn-CA125, 平分型-CA125

Abstract:

Abstract: CA125 is the most important serum biomarker for the diagnosis of ovarian cancer. However，its low specificity has been the main drawback. CA125 molecule is a huge mucin，with large amount of glycan modifications. Due to the unique glycan structures synthesized by malignant cells，CA125 molecules produced by ovarian cancer carry glycan chains that are different from those in benign gynecological diseases. These CA125 subtypes may serve as better serum biomarkers for ovarian cancer diagnosis.

Key words: ovarian cancer, CA125, glycosylation, Tn-CA125, bisecting-CA125

中图分类号:

R737.3

徐丛剑，王宜生，杨子健. CA125在卵巢癌诊断中的应用困境与突破[J]. 中国实用妇科与产科杂志, DOI: 10.7504/fk2016040110.

XU Cong-jian, WANG Yi-sheng，YANG Zi-jian.. Obstacles and breakthroughs in application of CA125 to ovarian cancer diagnosis.[J]. Acta Metallurgica Sinica, DOI: 10.7504/fk2016040110.

参考文献

[1] Cramer DW, Bast RC Jr, Berg CD, et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens [J]. Cancer Prev Res (Phila), 2011, 4: 365-374.

[2]    Wellmont Health System. Did termination of efficient nurse violate public policy?[J]. Nurs Law Regan Rep, 2011, 51: 1.

[3]    Nolen BM, Lokshin AE. Multianalyte assay systems in the differential diagnosis of ovarian cancer [J]. Expert Opin Med Diagn, 2012, 6: 131-138.

[4]    Nunez J, Nunez E, Consuegra L, et al. Carbohydrate antigen 125: an emerging prognostic risk factor in acute heart failure?[J]. Heart, 2007, 93: 716-721.

[5]    Chaube A, Tewari M, Singh U, et al. CA 125: a potential tumor marker for gallbladder cancer [J]. J Surg Oncol, 2006, 93: 665-669.

[6]    Kalantri Y, Naik G, Joshi SP, et al. Role of cancer antigen-125 from pleural & ascitic fluid samples in non malignant conditions [J]. Indian J Med Res, 2007, 125: 25-30.

[7] Patrelli TS, Berretta R, Gizzo S, et al. CA 125 serum values in surgically treated endometriosis patients and its relationships with anatomic sites of endometriosis and pregnancy rate [J]. Fertil Steril, 2011, 95: 393-396.

[8]    Bon GG, Kenemans P, Verstraeten AA, et al. Maternal serum CA125 and CA15-3 antigen levels in normal and pathological pregnancy [J]. Fetal Diagnosis Therapy, 2001, 16: 166-172.

[9]    Park Y, Lee JH, Hong DJ, et al. Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases [J]. Clin Biochem, 2011, 44: 884-888.

[10]   Haga Y, Sakamoto K, Egami H, et al. Evaluation of serum CA125 values in healthy-individuals and pregnant-women [J]. Am J the Med Sci, 1986, 292: 25-29.

[11]    Pauler DK, Menon U, McIntosh M, et al. Factors influencing serum CA125II levels in healthy postmenopausal women [J]. Cancer Epidemiol Biomark Prev, 2001, 10: 489-493.

[12]   Moss EL, Hollingworth J, Reynolds TM. The role of CA125 in clinical practice [J]. J Clin Pathol, 2005, 58: 308-312.

[13]   Yin BWT, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen - identification as a new mucin, MUC16 [J]. J Bio Chem, 2001, 276: 27371-27375.

[14]   O'Brien TJ, Beard JB, Underwood LJ, et al. The CA 125 gene: an extracellular superstructure dominated by repeat sequences [J]. Tumor Biol, 2001, 22: 348-366.

[15]    O'Brien TJ, Beard JB, Underwood LJ, et al. The CA 125 gene: a newly discovered extension of the glycosylated N-terminal domain doubles the size of this extracellular superstructure [J]. Tumor Biol, 2002, 23: 154-169.

[16]   Akita K, Tanaka M, Tanida S, et al. CA125/MUC16 interacts with Src family kinases, and over-expression of its C-terminal fragment in human epithelial cancer cells reduces cell-cell adhesion [J]. Eur J Cell Biol, 2013, 92: 257-263.

[17]   Lloyd KO, Yin BWT, Kudryashov V. Isolation and characterization of ovarian cancer antigen CA 125 using a new monoclonal antibody (VK-8): identification as a mucin-type molecule [J]. Int J Cancer, 1997, 71: 842-850.

[18]   Nustad K, Lebedin Y, Lloyd KO, et al. Epitopes on CA 125 from cervical mucus and ascites fluid and characterization of six new antibodies - third report from the ISOM TD-1 workshop [J]. Tumor Biol, 2002, 23: 303-314.

[19]   Wong NK, Easton RL, Panico M, et al. Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125 [J]. J Biol Chem, 2003, 278: 28619-28634.

[20]    Jankovic MM, Tapuskovic BS. Molecular forms and microheterogeneity of the oligosaccharide chains of pregnancy-associated CA125 antigen [J]. Human Reprod, 2005, 20: 2632-2638.

[21]    Jankovic MM, Milutinovic BS. Glycoforms of CA125 antigen as a possible cancer marker [J]. Cancer Biomark, 2008, 4: 35-42.

[22]   Aoyagi Y, Tamura Y, Suda T. History and recent progress in evaluation of the fucosylated alpha-fetoprotein fraction [J]. J Gastroenterol Hepatol, 2011, 26: 615-616.

[23]   Duc HN, van Trommel NE, Sweep FC, et al. Clinical utility of hyperglycosylated hCG in serum taken before hydatidiform mole evacuation to predict persistent trophoblastic disease [J]. Int J Biol Markers, 2006, 21: 45-49.

[24]   Wang PH, Lee WL, Juang CM, et al. Altered mRNA expressions of sialyltransferases in ovarian cancers [J]. Gynecol Oncol, 2005, 99: 631-639.

[25]   Yanagi M, Aoyagi Y, Suda T, et al. N-acetylglucosaminyltransferase V as a possible aid for the evaluation of tumor invasiveness in patients with hepatocellular carcinoma [J]. J Gastroenterol Hepatol, 2001, 16: 1282-1289.

[26]   Kitada T, Miyoshi E, Noda K, et al. The addition of bisecting N-acetylglucosamine residues to E-cadherin down-regulates the tyrosine phosphorylation of beta-catenin [J]. J Biol Chem, 2001, 276: 475-480.

[27]   Brockhausen I. Pathways of O-glycan biosynthesis in cancer cells [J]. Biochim Biophys Acta, 1999, 1473: 67-95.

[28]   Van Elssen C, Frings PWH, Bot FJ, et al. Expression of aberrantly glycosylated mucin-1 in ovarian cancer [J]. Histopathology, 2010, 57: 597-606.

[29]   Takahashi M, Kuroki Y, Ohtsubo K, et al. Core fucose and bisecting GlcNAc, the direct modifiers of the N-glycan core: their functions and target proteins [J]. Carbohydr Res, 2009, 344: 1387-1390.

（2016-03-03收稿）